Olaparib

The FDA expanded the approval of olaparib to include a new breast cancer indication.

SAN FRANCISCO  — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, spoke with Healio about the ongoing HOPE trial.

Susan M. Domchek, MD, executive director of the Basser Center for BRCA and the director of the MacDonald Cancer Risk Evaluation Center at Penn Medicine, spoke with Healio about updated results from the OlympiaA trial.

The FDA granted priority review to olaparib for adjuvant treatment of certain patients with high-risk breast cancer.

A randomized phase 3 study that assessed the addition of olaparib to abiraterone as first-line treatment for men with metastatic castration-resistant prostate cancer met its primary endpoint, according to the agent’s manufacturer.

In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.

Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with heavily pretreated isocitrate dehydrogenase-mutant high-grade glioma, according to results of the phase 2 OLAGLI study.

In this video, Holly Pederson, MD, assistant professor of medicine in the Cleveland Clinic Lerner College of Medicine of Case Western University, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.

In this video, Daphna Yael Spiegel, MD, an instructor in radiation oncology at Beth Israel Deaconess Medical Center, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.